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Abstract
Background: The efficacy of 2, 3, 5, 4′-tetrahydroxystilbene-2-O-β-D-glucoside (TSG) treatment on cognitive decline
in individuals with Alzheimer’s disease (AD) has not been investigated. Therefore, we systematically reviewed the
effect of TSG on cognitive deficits in a rodent model of AD.
Methods: We identified eligible studies published from January 1980 to April 2015 by searching seven electronic
databases. We assessed the study quality, evaluated the efficacy of TSG treatment, and performed a stratified
meta-analysis and meta-regression analysis to assess the influence of study design on TSG efficacy.
Results: Among a total of 381 publications, 18 fulfilled our inclusion criteria. The overall methodological quality
of these studies was poor. The meta-analysis revealed a statistically significant benefit of TSG on acquisition memory
(standardized mean difference [SMD] = −1.46 (95 % CI: −1.81 to −1.10, P < 0.0001) and retention memory (SMD =1.93
(95 % CI: 1.40 to 2.46, P < 0.0001) in experimental models of AD. The stratified analysis revealed a significantly higher
effect size for both acquisition and retention memory in studies that used mixed sex models and a significantly higher
effect size for acquisition memory in studies that used transgenic models.
Conclusions: Our meta-analysis highlights a significantly better treatment effect in rodent AD models that received
TSG that in those that did not. These findings indicate a potential therapeutic role of TSG in AD therapy. However,
additional well-designed and detailed experimental studies are needed to evaluate the safety of TSG.
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Background
Alzheimer’s disease (AD) is a major public health prob-
lem and a leading cause of disability [1, 2]. The number
of people affected by AD is increasing rapidly worldwide,
and more than 35 million people currently have AD. By
2050, the prevalence of AD is expected to quadruple to
1 in 85 people, of which 43 % are expected to need a
high level of care. World Alzheimer Report 2015 showed
that the total estimated worldwide cost of dementia is
$818 billion, and it will reach the trillion dollar mark by
2018 [3]. The clinical characteristics of AD are memory
loss and impairment of at least one other cognitive
domain [4]. Memory dysfunction is generally the first
symptom of AD, and it is generally the most severe
cognitive impairment. Mounting evidence indicates that
the severity of memory dysfunction correlates strongly
with the presence of beta-amyloid plaques and intracel-
lular tau and neocortical neurofibrillary tangles [5, 6].
Despite massive research effort to elucidate the causes
and mechanisms underlying AD, including recent ad-
vances in our understanding of its molecular pathology,
effective treatment remains elusive, and none of the
existing drugs are able to halt its progression [7, 8]. Con-
sequently, there is a growing interest in new therapeutic
strategies for the treatment of AD [9].
Polygonum multiflorum Thunb (PM) is a traditional
Chinese herb that has been used widely as an anti-aging
drug in the Orient since ancient times. TSG (2, 3, 5, 4′-
tetrahydroxystilbene-2-O-β-D-glucoside), a monomer of
stilbene, is one of the main components extracted from
the root of PM [10]. TSG can cross the blood–brain barrier
and has protective effects on hippocampal synaptic
plasticity in vitro [11, 12] and in vivo [13]. Recent studies
have also shown that TSG reduces the overexpression of
amyloid precursor protein (APP) [14], inhibits reactive
oxygen species generation [15], and attenuates cognitive
impairment in several animal models of AD, including age-
advanced rats [11], APP transgenic mice [16], amyloid-β1–
42-injected rats [12], and aluminium-exposed rats [14].
No systematic studies have investigated the effect of
TSG on cognition in humans with AD. Thus, in the
absence of systematic studies investigating TSG in
humans, it is not appropriate to state that studies are
needed to confirm the benefits of TSG because there are
no findings to confirm. It is more appropriate to state
that studies must be conducted to identify a potential
benefit. Systematic reviews of animal studies synthesize
the available evidence in an unbiased manner to provide
evidence for the potential translational value of effective
therapeutic interventions in animal models to humans
[17], contribute to models of clinically relevant prob-
lems, and facilitate decisions regarding the design and
conduct of subsequent human clinical trials [18]. There-
fore, the aim of the current study was to perform a
robust systematic review and meta-analysis of all avail-
able experimental evidence concerning the effects of
TSG on cognitive impairment in animal models of AD




On April 3, 2015 we searched seven electronic databases
(PubMed, Web of Science, MEDLINE, Google Scholar,
Embase, CNKI, and Wanfang data). All searches were re-
stricted to literature published between January 1980 and
April 2015. The following terms were included in the
searches: “Alzheimer’s disease” (or “Alzheimer disease”,
“dementia”, “Alzheimer”, “Alzheimers” or “Alzheimer’s”)
and “tetrahydroxystilbene glucoside” (or “Polygonum
multiflorum Thunb”, “Radix Polygonum Multiform”,
“tetrahydroxy stilbene glucoside”, “2, 3, 5, 4′-tetrahy-
droxystilbene-2-O-β-D-glucoside”, or “TSG”). We limited
our search results to animal studies. Additional relevant
publications were identified from the reference lists of the
resulting research articles and reviews. Bias was prevented
by the a priori defined inclusion and exclusion criteria de-
scribed in Table 1. Two investigators (SC and PW) assessed
the titles and abstracts of the studies and obtained copies of
the articles describing controlled studies of TSG or its ana-
logues in animal models of AD.
Data extraction
The following information was extracted from each in-
cluded study by two investigators: animal species; sex; type
of AD model; sample size; dose, method, and timing of
TSG administration; main experimental groups; interven-
tion regime (i.e., administration route and number of in-
jections); and cognitive outcome assessments.
Any studies that reported effects of TSG on learning
and memory abilities using an animal model of AD were
included. The cognitive outcomes were assessed by the
Morris water maze, passageway water maze, passive avoid-
ance task, and Y maze experiment, among others, which
are commonly used to evaluate spatial learning/memory in
both mice and rats [19, 20]. The details of the individual
study characteristics were extracted from each publication.
When a single publication included groups with different
TSG doses or different AD models across groups, these
data were extracted and considered independent experi-
ments. Because the learning trials to assess memory func-
tion were conducted over 5 days, the final test indicates the
learning ability of rats/mice [21]. Therefore, we extracted
the data for the final time point only when memory func-
tion was assessed at a different time point. If any informa-
tion was missing, then the study investigators attempted to
obtain the information from the study authors. If these data
were not available, then we excluded the study from the
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analysis. If the data were presented in graphical form only,
then we contacted the authors to request the numerical
values. If numerical values could not be obtained, then the
numerical values were estimated from the graphs using
digital ruler software.
Methodological study quality
The methodological quality of the studies was assessed
based on a checklist of the Collaborative Approach to
Meta-Analysis and Review of Animal Data from Experi-
mental Studies (CAMARADES), as previously described,
with minor modifications [22]. One point was assigned
for written evidence of each of the criteria described in
Table 2.
Although a large number of tools is currently used to
assess the quality of animal studies, most instruments
assess study quality and internal and external validity
simultaneously [23]. No tools that have been identified
that are able to assess internal validity alone. Therefore,
in addition to the modified CAMARADES checklist, we
used another previously described checklist [24, 25] to
assess study quality based on the study characteristics,
such as the age, species, and sex of the animals used,
and the dose and duration of TSG supplementation
(Table 3). The quality of all studies was assessed inde-
pendently by two reviewers (PW and SC).
Statistical analysis
The global estimated effect of TSG treatment on cognitive
outcomes was calculated using the standardized mean dif-
ference (SMD) and 95 % confidence intervals (CI), which is
used as a summary statistic in meta-analyses when studies
assess the same outcome but measure the outcome in dif-
ferent ways, based on the guidelines in the Cochrane
Handbook for Systematic Reviews of Interventions [26].
The SMD is equal to the difference in mean outcomes be-
tween groups divided by the standard deviation of out-
comes among participants and is reported in units of
standard deviation. Negative SMD effect sizes indicate a
positive efficacy for acquisition memory, whereas positive
SMD effect sizes indicate a positive efficacy for retention
memory. Within- and between-study heterogeneity was
evaluated using Cochran’s Q-statistic, P < 0.10, to indicate
heterogeneity among studies [25]. The statistical hetero-
geneity across studies was assessed using the I2 statistic,
with values of 75, 50, and 25 % representing high, moder-
ate, and low heterogeneity, respectively. A value ≥50 % sug-
gests unacceptable heterogeneity among the studies [27]. A
random-effects model was used to pool the SMD when the
heterogeneity was significant (I2 ≥ 50 %); otherwise, a fixed
effects model was applied.
Subgroup analyses were also used to identify associa-
tions between relevant study characteristics, such as spe-
cies, sex, TSG dose, and study quality, as possible sources
of heterogeneity. Heterogeneity and the x2 distribution
with n-1° of freedom (df), where n equals the number of
groups, was used to assess the differences in mean effect
sizes between groups. To adjust the values for multiple
comparisons, we used Bonferroni’s correction methods
(declared significance =1 − (1 − denoted significance)∧(1/
number of comparisons)), which was appropriate for the
number of analyses conducted [28]. The denoted signifi-
cance level was set at P < 0.05. The declared P values for
this study were 0.0017 for acquisition memory and 0.0037
for retention memory.
Finally, meta-regression analyses were conducted to re-
veal potential sources of heterogeneity in the efficacy of
TSG when high heterogeneity was present. The following
variables were included in the meta-regression analyses:
species, sex, TSG dose, and study quality. To allow for
multiple comparisons, the significance was set at P < 0.01.
All statistical analyses were performed using the Stata




A total of 381 publications were identified, of which 18
met our inclusion criteria [11, 12, 14, 16, 29–42]. Our
meta-analysis is based on these 18 studies, which include
39 comparisons of acquisition memory and 15 compari-
sons of retention memory (Fig. 1).
Study characteristics
Of the 18 included studies (Table 4), 13 were published
in Chinese academic journals and the remainder were
Table 1 Criteria for study inclusion/exclusion
Inclusion criteria Exclusion criteria
(1) TSG were administered. (1) TSG were not administered.
(2) Experimental AD was
induced in rodents.
(2) Other types of animals
(e.g., sheep, cats, and dogs)
were used.
(3) treatment group was treated
with TSG, and control group
was administered a placebo.
(3) Treatment group was
administered another
neuroprotective agent
in addition to TSG.
(4) Cognitive function was
measured by the MWM,
passageway water maze,
passive avoidance task,
Y maze experiment etc.
(4) Treatment group was
administered another
Chinese Traditional Medicine
in addition to TSG.
(5) Article was published in
English or Chinese language.




(6) No control group was used.
(7) Duplicate publications or
data presented in duplicate
by additional publications.
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published in English. The characteristics of these studies
are presented in Table 1. A total of 10 studies used mice
(3 Balb/c mice [31, 32, 36], 2 Kunming mice [33, 38], 3
PDAPPV717I transgenic mice [16, 29, 30], and 2 senes-
cence accelerated prone mice/8 [34, 35]), 7 studies used
Sprague-Dawley rats [11, 12, 14, 37, 39, 41, 42] and 1
study used Wistar rats [40]. Female animals were used
in 3 studies [31, 32, 36], male animals were used in 11
studies [11, 12, 14, 34, 35, 37–42], and both males and
females were used in 4 studies [16, 29, 30, 33]. Five stud-
ies used a transgenic model [16, 29, 30, 34, 35], 3 studies
used a D-galactose-induced model [31–33], 2 studies
used a cholinergic damage model [37, 38], 2 studies used
an age-advanced model [11, 42], 5 studies used an
amyloid-β1-42-injected model [12, 36, 39, 41, 42], 1
study used an aluminium chloride-exposed model [14],
and 1 study used a hypercholesterolemia model [40]. To
assess learning and memory, 14 studies used the Morris
water maze test, and all of these studies used a hidden
platform during the probe phase [12, 16, 29–38, 40, 42].
One study used a passageway water maze [11], 1 study
used passive avoidance task [14], and 2 studies used a Y
maze experiment [39, 41].
Study quality
According to the modified CAMARADES checklist, the
median quality score for the 18 included studies was poor
(5.692; interquartile range: 5–6), with scores ranging from
4 to 7. No study received a score of 0 or 10. Five studies
received scores indicating high quality [12, 14, 16, 39, 42].
One study reported monitoring of physiological pa-
rameters [12]. One study mentioned allocation con-
cealment [16]. Two studies [31, 37] did not report
randomization of animals into treatment groups. Ten
studies [16, 29, 30, 32–35, 37, 38, 40] assessed dose-
response relationships. Four studies [12, 14, 39, 42]
stated no potential conflicts of interest. Unfortunately,
no studies described the calculation of the sample size re-
quired to achieve sufficient power to detect differences.
According to our secondary criteria, the average quality
score of the included studies was 16.74, with scores ran-
ging from 15 to 19. Six studies [12, 14, 37, 39, 40, 42]
received a score of 15, and two studies received a score of
19 [16, 36]. Six studies did not report the age of the ani-
mals [12, 14, 37, 39, 40, 42]. Only one study [16] reported
blinded outcome assessments. No studies mentioned any
dropouts. No studies mentioned whether the order of the
outcome assessments was randomized across groups.
Overall efficacy
For acquisition memory, the global estimated effect of
TSG was −1.46 (95 % CI: −1.81 to −1.10, P < 0.0001),
with significant heterogeneity among studies (heterogen-
eity: x2 = 216.17, df = 38, P < 0.00001, I2 = 82 %; Fig. 2a).
Table 2 The CAMARADES quality items
Authors & Year ➀ ➁ ➂ ➃ ➄ ➅ ➆ ➇ ➈ ➉ Quality score
Zhang et al. 2006 [17] √ √ √ √ √ √ √ 7
Zhou et al. 2012 [13] √ √ √ √ √ √ √ 7
Zhang et al. 2006 [27] √ √ √ √ √ √ 6
Xing et al. 2006 [28] √ √ √ √ √ √ 6
Xie et al. 2005 [29] √ √ √ √ 4
Chu et al. 2005 [30] √ √ √ √ √ √ 6
Huang et al. 2008 [31] √ √ √ √ √ 5
Huang et al. 2008 [32] √ √ √ √ √ 5
Liu et al. 2012 [33] √ √ √ √ √ √ 6
Chu et al. 2004 [34] √ √ √ √ √ 5
Ye et al. 2003 [35] √ √ √ √ √ 5
Ye et al. 2005 [36] √ √ √ √ √ √ 6
Wang et al. 2007 [12] √ √ √ √ √ 6
Luo et al. 2009 [15] √ √ √ √ √ √ √ 7
Hou et al. 2011 [40] √ √ √ √ √ √ √ 7
Luo et al. 2010 [37] √ √ √ √ √ 5
Zhao et al. 2004 [38] √ √ √ √ √ √ √ 7
Luo et al. 2012 [39] √ √ √ √ √ 5
(1) peer reviewed publication; (2) presence of randomization of subjects into treatment groups; (3) assessment of dose–response relationship; (4) blinded
assessment of behavioral outcome; (5) monitoring of physiological parameters such as body temperature; (6) calculation of necessary sample size to achieve
sufficient power; (7) statement of compliance with animal welfare regulations; (8) avoidance of anesthetic agents with marked intrinsic neuroprotective properties
(e.g., ketamine); (9) statement of potential conflict of interests; (10) use of a suitable animal model
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√ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √
Outcome measures relevant for
AD research
√ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √
Are the characteristics of study
population clear?
Species √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √
Background/generation √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √
Sex (and distribution) √ √ √ √ √ N √ N √ √ √ √ √ √ √ √ √ √
Age √ N √ √ √ √ N √ N √ √ √ √ N √ N N √
Presence and correct control
group?
√ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √
Where the groups similar at
baseline (if not randomized
think of weight and sex etc.)?
√ √ √ √ N √ √ √ √ √ N √ ? √ √ √ √ √
Is the experiment randomized? √ √ √ √ N √ √ √ √ √ N √ √ √ √ √ √ √
Kind of supplement mentioned
(TSG)?
√ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √
Age when supplementation
started mentioned?
√ N √ √ √ √ N √ N √ √ √ √ N √ N N √
Duration of supplementation
clear and specified?
√ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √
Amount of TSG mentioned √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √
Administration route specified √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √
Is the timing of the
supplementation during the
day specified and similar in
both groups?
√ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √
Methods used for outcome
assessment the same in
both groups ?
√ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √
Drop outs described for each
group separately?
N N N N N N N N N √ N N N N N N N N


















Table 3 The second quality items (Continued)
Was the outcome assessment
randomized across the groups?
N N N N N N N N N N N N N N N N N N
Total number of animals
included in statistical analyses
clear?
√ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √
Age of sacrificing animals
mentioned?
√ N √ √ √ √ N √ N √ N √ √ N √ N N √


















For retention memory, the global estimated effect of
TSG was 1.93 (95 % CI: 1.40 to 2.46, P < 0.0001), with
significant heterogeneity among studies (x2 = 56.97, df =
14, P < 0.0001; I2 = 75 %; Fig. 2b).
Stratified meta-analysis
Subgroup analyses were conducted to assess the degree
to which the methodological differences between trials
may have systematically influenced differences observed
in the primary treatment outcomes. The results of the
stratified analyses are described in Table 5.
We examined the protective effects of TSG on different
rodent species. For both acquisition and retention mem-
ory, the effect size was significantly higher in studies that
used Sprague-Dawley rats than in studies that used other
species (Fig. 3a and b); P = 0.0002 for acquisition memory
and P < 0.00001 for retention memory, respectively). The
effect size was −2.78 (95 % CI: −4.06 to −1.51) for acquisi-
tion memory and 3.60 (95 % CI: 2.63 to 4.57) for retention
memory in studies that used Sprague-Dawley rats.
We also examined the effect size of TSG on acquisition
memory and retention memory in studies that used male,
female, or mixed sex animals. The effect size on acquisition
memory was significantly higher in studies that used mixed
sex animals than in those that used male or female animals
only (x2 = 18.45, df = 2, P < 0.00001; Fig. 3c). The effect size
on retention memory was examined in studies that used
mixed sex or male animals only because limited data were
available from studies with female animals only. The effect
size was higher in studies that used mixed sex animals
(−2.06, 95 % CI: 1.15 to 2.98) than in those that used male
animals only, but this difference was not significant (x2 =
0.21, df = 1, P = 0.65; Fig. 3d). A significant effect size for ac-
quisition memory was observed in both transgenic models
Fig. 1 Flow diagram of the study search process
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Table 4 Characteristics of included studies

















Transgenic model TSG/water 1) AD plus water 120 (TSG -L), &
240 (TSG-H) mg/kg
body wt
Intragastrically/4 months 7 MWM
2) AD plus TSG -L
3) AD plus TSG-H




Male Aβ infused rats TSG/NS 1) AD plus NS 25 mg/kg body wt Intragastrically/4 months 7 MWM







Transgenic model TSG/water 1) AD plus water 50 mg (TSG -L),
100 mg (TSG -M),&
200 mg (TSG-H) g/kg
body wt
Intragastrically/4 months 6 MWM
2) AD plus TSG -L
3) AD plus TSG -M
4) AD plus TSG-H






Transgenic model TSG/water 1) AD plus water 0.05 (TSG -L), &
0.20 (TSG-H) g/kg
body wt
Intragastrically/6 months 6 MWM
2) AD plus TSG -L
3) AD plus TSG-H
Xie et al. 2005
[29]
BALB/c mouse (n = 12) Female D-galactose infused mice TSG/water 1) AD plus water 0.05 g/kg body wt Intragastrically/2 months 4 MWM
2) AD plus TSG
Chu et al. 2005
[30]
Balb/c mouse (n = 52) Female D-galactose infused mice TSG/water 1) AD plus water 33 mg (TSG-L),
100 mg (TSG-M),&
300 mg (TSG-H) g/kg
body wt
Intragastrically/2 months 6 MWM
2) AD plus TSG -L
3) AD plus TSG -M
4) AD plus TSG-H
Huang et al.
2008 [31]
Kunming mouse (n=40) Female &
Male
D-galactose Infused mice TSG/water 1) AD plus water 33 mg (TSG-L),
100 mg (TSG-M),&
300 mg (TSG-H) g/kg
body wt
Intragastrically/2 months 5 MWM
2) AD plus TSG –L
3) AD plus TSG –M
4) AD plus TSG-H
Huang et al.
2008 [32]
SMAP mouse Male Transgenic model TSG/NS 1) AD plus NS 33 mg (TSG-L),
100 mg (TSG-M),&
300 mg (TSG-H) g/kg
body wt
Intragastrically/50 days 5 MWM
2) AD plus TSG –L
3) AD plus TSG –M
4) AD plus
TSG-H
Liu et al. 2012
[33]
SMAP mouse Male Transgenic model TSG/NS 1) AD plus NS 33 mg (TSG-L),
100 mg (TSG-M),&
300 mg (TSG-H) g/kg
body wt
Intragastrically/50 days 6 MWM
2) AD plus TSG –L
3) AD plus TSG –M


















Table 4 Characteristics of included studies (Continued)
Chu et al. 2004
[34]
Balb/c mouse (n = 52) Female Aβ infused mice TSG/NS 1) AD plus NS 0.1 g/kg body wt Intragastrically/8 weeks 5 MWM
2) AD plus TSG
Ye et al. 2003
[35]
Sprague-Dawley
rat (n = 43)
Male ibotenic acid infused rats TSG/NS 1) AD plus water 30 mg (TSG-L),
60 mg (TSG-M),&
120 mg (TSG-H) g/kg
body wt
Intraperitoneally/1 month 5 MWM
2) AD plus TSG -L
3) AD plus TSG -M
4) AD plus TSG-H
Ye et al. 2005
[36]
Sprague-Dawley
rat (n = 29)
Male scopolamineinfused rats TSG/NS 1) AD plus water 33 mg (TSG-L) &
100 mg (TSG-H) g/kg
body wt
Intraperitoneally/2 months 6 MWM
2) AD plus TSG -L
3) AD plus TSG-H
Wang et al. 2007
[12]
Sprague-Dawley rat Male Aged rats TSG/water 1) AD plus water 30 mg(TSG-L), 60 mg
(TSG-M) g/kg body wt
Intragastrically/12 W 6 PWM
2) AD plus TSG -L
3) AD plus TSG-H
Luo et al. 2009
[15]
Sprague-Dawley rat Male aluminum chloride
exposure rats
TSG/water 1) AD plus water 4000 mg g/kg body
wt
Intragastrically/20 W 7 PAT
2) AD plus TSG
Hou et al. 2011
[40]
Sprague-Dawley rat Male Aged rats TSG/NS 1) AD plus NS 50 mg g/kg body wt Intragastrically/20 W 7 MWM
2) AD plus TSG
Luo et al. 2010
[37]
Sprague-Dawley rat Male Aβ infused rats TSG/NS 1) AD plus NS 100 mg g/kg body wt Intragastrically/3 W 5 YEM
2) AD plus TSG
Zhao et al. 2004
[38]
Wistar rat Male Hypercholestero-lemia
rats
TSG/NS 1) AD plus NS 30 mg (TSG-L),
60 mg (TSG-M),&
120 mg (TSG-H) g/kg
body wt
Intragastrically/10 W 7 MWM
2) AD plus TSG -L
3) AD plus TSG -M
4) AD plus TSG-H
Luo et al. 2012
[39]
Sprague-Dawley rat Male Aβ infused rats TSG/NS 1) AD plus NS 50 mg g/kg body wt Intragastrically/3 W 4 YEM
2) AD plus TSG


















(−1.46, 95 % CI: −1.94 to −0.98, P < 0.0001) and non-
transgenic models (−1.46, 95 % CI: −2.00 to −0.91, P <
0.0001); no significant difference was observed between
models (x2 = 0.00, df = 1, P = 0.99; Fig. 3e). A slightly higher
effect size for retention memory was observed in non-
transgenic models than in transgenic models, but no signifi-
cant differences were observed between models (x2 = 0.001,
df = 1, P = 0.93; Fig. 3f).
Next, we analysed the efficacy of different doses of
TSG on cognitive performance. For both acquisition and
retention memory, significant beneficial effects were
found for all doses of TSG, with a maximum effect at
the lowest dose for both acquisition memory (−1.92,
95 % CI: −2.52 to −1.32) and retention memory (2.23,
95 % CI: 1.34 to 3.11). However, no significant differ-
ences among doses were detected for either acquisition
memory (x2 = 8.48, df = 3, P = 0.04; Fig. 4a) or retention
memory (x2 = 3.86, df = 2, P = 0.15; Fig. 4b).
The effect sizes for acquisition and retention memory
were also examined relative to the study quality score.
For acquisition memory, the effect size was significantly
higher in studies with a quality score of 7 (−3.82, 95 %
CI: −4.41 to −3.23) than in those with a quality score of
4, 5, or 6 (x2 = 101.37, df = 3, P < 0.00001); Fig. 4c). No
significant differences in effect size were observed rela-
tive to study quality for retention memory (x2 = 12.51,
df = 3, P = 0.006; Fig. 4d); however, the effect size was
highest for studies with a quality score of 4 (3.86, 95 %
CI: 1.66 to 6.05).
Meta-regression analyses
A multivariate random-effects regression with species,
sex, model, TSG treatment dose, and study quality score
was conducted to further explore the heterogeneity
among studies regarding acquisition and retention mem-
ory. For acquisition memory, the study quality score was a
significant source of heterogeneity (P < 0.05). For retention
memory, heterogeneity was independent of all tested fac-
tors (Table 6). Finally, we analysed the combined data for
acquisition and retention memory to determine whether
the study quality score was a significant source of hetero-
geneity. However, the results showed that the study quality
score was not a significant source of heterogeneity for the
combined data (coef: −.1396835; 95 % CI: −1.896979-
1.61761; t: −0.16).
Discussion
Systematic reviews of animal studies synthesize the avail-
able evidence in an unbiased manner to provide evi-
dence for the potential translational value of effective
therapeutic interventions in animal models to humans
[17], contribute to models of clinically relevant prob-
lems, and facilitate decisions regarding the design and
conduct of subsequent human clinical trials.
Systematic reviews of animal studies synthesize exist-
ing evidence in an unbiased manner to facilitate deci-
sions regarding the design and conduct of subsequent
human clinical trials [18]. To the best of our knowledge,
this is the first systematic review and meta-analysis to
examine the efficacy of TSG in animal models of AD.
This systematic review was performed according to the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses [43] flow diagram (Fig. 1). Although
small study effects and statistical heterogeneity were
present among the included studies, we found that TSG
may improve cognitive outcomes relevant to AD [44].
Subgroup analyses of stratified characteristics were
assessed to examine the variation in the effects of the
intervention, which would suggest that the stratifying
characteristic is a crucial factor for heterogeneity and
may affect the treatment efficacy. Based on current
guidelines, which recommend at least 10 studies per
characteristic to stratify subgroups [45], we were able to
conduct subgroup analyses of potential sex and species
differences, which revealed a higher effect of TSG on ac-
quisition and retention memory in Sprague-Dawley rats
than in other species, and less acquisition and retention
memory loss following TSG supplementation in studies
Fig. 2 Effects of TSG on acquisition memory (a) and retention memory (b). The horizontal lines represent the mean estimated effect sizes and
95 % CIs for each comparison. The vertical grey bars represent the 95 % CIs of the pooled estimated effect sizes
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Table 5 The results of stratified meta-analysis
Subgroups Acquisition memory Retention memory
Studies Participants Effect size [95 % CI] Subgroup differences Dtudies Participants Effect size [95 % CI] Subgroup differences
Animal species
APP mice 11 349 −1.84 [−2.62, −1.05] P = 0.0002 4 144 2.84 [1.35, 4.32] P < 0.00001
Balb/c mice 5 124 −0.45 [−0.80, −0.09]
Kunming mice 5 98 −0.84 [−1.27, −0.42] 3 60 1.12 [0.56, 1.67]
SMP8 mice 6 120 −0.79 [−1.17, −0.41] 6 120 1.36 [0.95, 1.77]
SD rats 9 208 −2.78 [−4.06, −1.51] 2 48 3.60 [2.63, 4.57]
Wistar rats 3 105 −1.35 [−1.17, −0.41]
Sex
Male 20 471 −1.59 [−2.12, −1.06] P < 0.00001 8 168 1.61 [1.17, 2.45] P = 0.65
Female 5 124 −0.45 [−0.80, −0.09]
Female & Male 14 409 −1.68 [−2.31, −1.05] 7 204 2.06 [1.15, 2.98]
Model
Untransgenic 22 535 −1.46 [−1.94, −0.98] P = 0.99 5 108 1.98 [0.88,3.08] P = 0.93
Transgenic 17 469 −1.46 [−2.00, −0.91] 10 264 1.92 [1.28, 2.56]
Dose
Less 100 mg 21 582 −1.92 [−2.52, −1.32] P = 0.04 8 216 2.23 [1.34, 3.11] P = 0.15
100 mg 11 270 −0.91 [−1.37, −0.45] 3 60 1.25 [0.69, 1.82]
200 mg 2 64 0.92 [−1.46, −0.39]
300 mg 4 88 −1.01 [−1.46, −0.56] 4 96 1.98 [0.92, 3.05]
Quality
4 2 60 −2.10 [−5.27, −1.08] P < 0.00001 1 12 3.86 [1.66, 6.05] P = 0.006
5 15 361 −1.26 [−1.64, −0.81] 6 120 1.15 [0.76, 1.55]
6 15 387 −0.63 [−0.83, −0.42] 3 60 1.56 [0.96, 2.16]


















that used mixed sex groups than in those that used only
male or female animals. In addition, TSG treatment was
similarly neuroprotective for acquisition and retention
memory in both transgenic and non-transgenic models.
However, we also found that the lowest dose of TSG
provided the greatest benefit in terms of acquisition and
retention memory, which is not consistent with a previ-
ously described dose-linear response curve [46]. This
finding suggests that effect size has been overstated in
studies that used lower doses of TSG.
The meta-regression analysis revealed that the hetero-
geneity was not due to the variables included in the
model. Sex, species, animal model, and TSG dose did
not affect the heterogeneity of either acquisition or re-
tention memory. The study quality score may explain
the heterogeneity in acquisition memory, but the hetero-
geneity could not be explained by the findings for reten-
tion memory or the combined data for acquisition and
retention memory. These results may be a consequence
of the small sample sizes in those studies and the limited
number of studies, reducing the reliability of the ana-
lysis. Therefore, we could not conclude that the study
quality is dependent on the outcome.
There are some limitations to our present meta-analyses.
First, our conclusions are limited by the availability of pub-
lished trials. We did not include unpublished data in our
Table 6 Metaregression analysis to identify sources of bias associated with study characteristics
Covariates Coef. Std. err. t P > |t| [95 % conf. interval]
(a) Acquisition memory
Quality score −.8748308 .2568104 −3.41 0.002 −1.400067 −.3495946
sex .6720335 .4156478 1.62 0.117 −.1780618 1.522129
dose .1827889 . 2101048 0.87 0.391 −.2469237 .6125015
special .24532 .1328595 1.85 0.075 −.0264082 .5170483
model .8326842 .7477604 1.11 0.294 −.8588674 2.524236
(b) Retention memory
Quality score .4047783 .3156139 1.28 0.224 −.2828853 1.092442
sex .7864006 .291455 2.70 0.019 1.421426 .1513747
dose −.4543919 .3441781 −1.32 0.211 −1.204292 .2955078
special .7864006 .291455 2.70 0.019 .1513747 1.421426
Fig. 3 Effect size stratified by animal species for (a) acquisition memory and (b) retention memory, according to animal gender. Effect size
stratified by gender for (c) acquisition memory and (d) retention memory stratified by the model method for (e) acquisition memory and (f)
retention memory. Grey bands represent the 95 % CIs for the global estimated effect sizes
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study. Although we attempted to identify all relevant
studies from both Western and Eastern countries, all
included studies were conducted within China, which may
limit generalizations based on our findings. In addition, it
has been reported that some Asian countries, including
China, publish unusually high proportions of positive re-
sults [27, 47]. Of the studies included in this meta-analysis,
most did not report negative findings. We conducted an
extensive search of unpublished material in an attempt to
obtain negative results, but no unpublished negative studies
were identified. We cannot exclude the possibility that
studies with negative findings remain unpublished because
significant positive findings are more likely to be published
than non-significant findings. A meta-analysis based on the
published literature may overestimate the efficacy of an
intervention [48]. Therefore, publication bias may exist in
our meta-analysis, although it seems unlikely that the direc-
tion or significance of our findings would be modified by
unacknowledged trials.
Second, we observed significant heterogeneity among
the study results. Although we used accepted techniques
for the meta-regression analysis to identify factors asso-
ciated with variability in the benefits of TSG treatment,
the statistical power of these analyses was relatively low
given the number of available trials. Unfortunately, for
retention memory, the adjusted R2 was 29.72 % due to
the limited number of studies. In addition, the covariates
included in the model could not explain the heterogeneity
more than would be expected by chance. Therefore, it was
impossible to accurately determine whether the ob-
served heterogeneity was independent of these factors.
The presence of heterogeneity highlights the need for
caution in interpreting the present findings [49].
Third, no trial exceeded 6 months in duration, which
is relatively short given that patients with AD may require
treatment with TSG for decades. Long-term treatment
may lead to adverse events or persistent or significant dis-
ability/incapacity. Furthermore, we focused on only the ef-
fect of TSG on cognitive deficits in animal models of AD,
largely due to insufficient data regarding the effect of TSG
on neuropathological changes (i.e., β-amyloid plaques and
neurofibrillary tangles) in AD.
Fourth, we assessed the methodological quality of
studies in accordance with previously described stan-
dards for the preclinical development of neuroprotective
drugs, with minor modifications [18]. Overall, we found
that the quality of the included studies was poor. Many
of the studies failed to report blinded outcome assess-
ments, which is recommended for open-label trials to
reduce bias. Patient, clinician, and/or assessor awareness
of the treatment assignment may influence outcome
reporting or measurements and introduce bias [50].
Moreover, although it is important to judge the efficacy
of a new drug or therapy, no study reported sample size
calculations [51], which should be calculated during the
planning phase of the study to evaluate the accuracy of a
priori estimates and assist in the design of future experi-
ments [52]. Furthermore, lower quality studies showed a
trend towards better retention memory outcomes. There-
fore, the global estimated effect of TSG on cognition may
be overstated in low quality studies. In addition, studies that
included female animals failed to describe their hormonal
Fig. 4 Effect size stratified by the dose of TSG for (a) acquisition memory and (b) retention memory according to animal gender. Effect size stratified
by quality score for (c) acquisition memory and (d) retention memory. Rey bands represent the 95 % CIs for the global estimated effect sizes
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cycle, which may influence behaviour, body physiology, and
cognitive and learning-related performance, and should be
accounted for in the experimental design (e.g., by increasing
power and/or balancing the randomization of animals
across groups) [24, 53].
Fifth, an increasing number of reports on adverse effects
and hepatotoxicity of PMT products have been reported
in patients [54]. TSG, the main water-soluble active com-
ponent of PMT, was considered the major cause of hep-
atotoxicity [55, 56]. Nonetheless, no study reported any
data on the safety and toxicity of TSG perhaps due to the
perception that herbal agents are safe because they are
natural products and have a long history of use. Along
with the medical use and researches of herbal medicines
increased, toxicity and safety of those medicinal materials
had become the crucial concerns [57]. It is essential to de-
sign additional well-designed and detailed experimental
studies to evaluate the safety of TSG before human clin-
ical studies and application.
Conclusions
Despite its limitations, this systematic review and meta-
analysis demonstrates that TSG may reduce cognitive
deficits in animal models of AD and indicate a potential
therapeutic role of TSG in AD therapy. However, add-
itional scientific experimental studies are needed to
evaluate the safety of TSG before human clinical studies
and application.
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